OBJECTIVE: Over ten million women are either pregnant or lactating in the United States at any time. The risks of medication use for these women are unique. In addition to normal physiologic changes that alter the pharmacokinetics of drugs, there is the concern of possible teratogenic and toxic effects on the developing fetus and newborn. This article reviews the risks and pharmacokinetic considerations for 11 broad-spectrum antibiotics that can be used to treat routine and life-threatening infections during pregnancy and lactation. 
A ntibiotics are among the most commonly prescribed prescription medications for pregnant and lactating women. 1 More than 10 million women are either pregnant or lactating in the United States at any one time, and they are administered antibiotics for many reasons. 2 Because of the special considerations associated with fetal and newborn development, these women constitute a uniquely vulnerable population for which the risks of medication use must be separately assessed.
In addition to the pharmacokinetic and pharmacodynamic changes that may occur during pregnancy and lactation that can alter the effectiveness of drugs, 3 there is the added concern of the possible teratogenic and toxic effects that medications may have on the developing fetus and newborn. In general, there is a dearth of pharmacokinetic and pharmacodynamic information regarding the use and proper dosing of Food and Drug Administration (FDA)-approved drugs in pregnant and lactating women, as well as limited data pertaining to the teratogenic potential and the fetal or neonatal toxicity of these marketed medications. Accordingly, sparse information must sometimes be assembled from diverse sources to address these issues.
Recently, the threat of bioterrorism has expanded the context in which the potential use of antibiotic medications may be needed. 4 Although the possibility of a large-scale bioterrorist attack in the United States is unlikely, the potential for widespread antibiotic use in this situation emphasizes the need for health care professionals to be familiar with the risks and benefits of administering antibiotics to pregnant and lactating women.
This article reviews the available information concerning the risks and special circumstances to be considered in pregnant and lactating women for a group of 11 broad-spectrum antibiotics (amoxicillin, chloramphenicol, ciprofloxacin, clindamycin, doxycycline, gentamicin, levofloxacin, penicillin G, penicillin VK, rifampin, and vancomycin). By using this information, better choices can be made for the treatment of different types of bacterial pathogens in these particularly vulnerable populations.
DATA SOURCES AND METHODS OF STUDY SELECTION
Information from FDA-approved product labels, the Teratogen Information Service, Shepard's Catalog of Teratogenic Agents, REPROTOX, Clinical Pharmacology, and the peer-reviewed literature were reviewed for information concerning the use of 11 antibiotics in pregnant and lactating women. The medical literature was queried with the PubMed search engine. Papers searched were published from January 1940 to November 2005, in any language. The search terms "[antibiotic name] and pregnancy," "[antibiotic name] and lactation,", and "[antibiotic name] and breastfeeding," were used, as was standard reference tracing. A total of 124 references were accessed through these sources that contained sufficient information concerning the numbers of subjects, methods of investigation, and findings to be useful for the purpose of drawing conclusions concerning pharmacokinetic parameters, teratogenic potential, and toxicity assessments of these drugs. All materials were restricted to information from nonproprietary sources that were available in the public domain. Additionally, information concerning the potential treatment options for exposures and diseases caused by possible agents of bioterrorism were obtained from materials published by the Centers for Disease Control and Prevention in Atlanta.
RESULTS
A description of the 11 broad-spectrum antibiotics and their general modes of action are provided in Table 1 .
All 11 antibiotics cross the placenta and enter the fetal compartment. For 5 of these, human umbilical cord blood levels are of the same order of magnitude as circulating maternal blood concentrations (chloramphenicol, clindamycin, gentamicin, rifampin, and vancomycin). For 4, the concentrations are of the same magnitude or higher in amniotic fluid as in maternal blood (ciprofloxacin, clindamycin, levofloxacin, and vancomycin) ( Table 2 ).
All 11 antibiotics are excreted in human breast milk. Limited information concerning the amount in breast milk was available for 8 antibiotics (ciprofloxacin, clindamycin, doxycycline, gentamicin, levofloxacin, penicillin G, penicillin VK, and rifampin). No quantitative data concerning breast milk concentrations were available for 3 (amoxicillin, chloramphenicol, and vancomycin) ( Table 2) .
Using the Teratogen Information Service classification system for teratogenic risk, 44 the teratogenic potential of the 11 antibiotics during human pregnancy ranged from "none" in 2 cases (penicillin G and VK) to "unlikely" in 6 (amoxicillin, chloramphenicol, ciprofloxacin, doxycycline, levofloxacin, and rifampin) to "undetermined" in 3 (clindamycin, gentamicin, and vancomycin). Assessments were based on data that were "good" for 2 (penicillin G and VK) to "fair" for 6 (amoxicillin, chloramphenicol, ciprofloxacin, doxycycline, levofloxacin, and rifampin) to "limited" for 2 (clindamycin and gentamicin) to "very limited" for 1 (vancomycin) . A summary of the human and animal data contributing to these assessments is shown in Table 3 (Table 4) were "B" in 5 cases (amoxicillin, clindamycin, penicillin G, penicillin VK, and vancomycin), "C" in 5 cases (chloramphenicol, ciprofloxacin, gentamicin, levofloxacin, and rifampin), and "D" in 1 case (doxycycline) ( Table 3 ). In addition to the published literature, proprietary data were used to establish the FDA pregnancy category for these drugs.
Despite numerous concerns regarding the potential for maternal and fetal or neonatal toxicity of these 11 drugs-including idiosyncratic and dose-related bone marrow suppression with chloramphenicol, arthropathies and bone and cartilage damage with ciprofloxacin and levofloxacin, dental staining and hepatic necrosis with doxycycline, and ototoxicity and nephrotoxicity with gentamicin and vancomycin-none of these toxicities has been documented in human mothers or offspring either during pregnancy or breastfeeding with these antibiotics (Table  3) .
Very limited information was available pertaining to maternal pharmacokinetics in pregnancy for 8 antibiotics (amoxicillin, ciprofloxacin, clindamycin, gentamicin, levofloxacin, penicillin G, penicillin VK, and vancomycin), and none was available for 3 (chloramphenicol, doxycycline, and rifampin) ( Table  2 ). For 4 antibiotics (amoxicillin, gentamicin, penicillin G, and penicillin VK), lower circulating drug concentrations were measured in pregnant women than nonpregnant, suggesting that a shorter dosing interval or increased maternal dose or both may be necessary to obtain similar circulating drug concentrations as for women in the nonpregnant state. In the case of ciprofloxacin and levofloxacin, circulating concentrations were generally reduced in pregnant women, also suggesting that an increased maternal dose or a shorter dosing interval or both may be necessary. In 3 cases (chloramphenicol, gentamicin, and vancomycin), therapeutic drug monitoring of serum peak and trough levels is recommended to assess circulating drug levels. In 1 case (clindamycin), the standard pharmacokinetic parameters did not change appreciably during the first, second, or third trimester of pregnancy (Table 2) . Very little pharma- [5] [6] [7] Penicillins transferred to the fetus and amniotic fluid reach therapeutic levels. 5 Excreted in human breast milk in small amounts. 8 Considered "usually compatible with breastfeeding." 9 † Following therapeutic doses, mean human milk concentrations were 0.1-0.6 g/mL.
10
No adverse effects seen in nursing infants whose mothers have been treated with amoxicillin.
Shorter dosing interval and/ or increased dose have been suggested during pregnancy to attain similar plasma concentrations as for nonpregnant women. 6, 11 Penicillins are primarily renally excreted via tubular secretion and glomerular filtration. Volume of distribution and renal clearance are increased during the 2nd and 3rd trimesters. 6, 11 Chloramphenicol Gram positives, gram negatives, anaerobes, chlamydia, rickettsiae Crosses the human placenta readily.
Umbilical cord serum concentrations 29-106% of maternal levels.
12
Excreted in human breast milk. [13] [14] [15] In 5 patients with minor obstetrical lacerations who received 1 g PO qD for 8 days, mean milk concentrations were 0.5-2.8 g/mL.
In 5 patients receiving 2 g PO qD for 8 days for mastitis, mean milk concentrations were 1.8-6.1 g/mL.
13
Human milk concentrations are 51-62% of blood levels. 44, [20] [21] [22] [23] In 54 women undergoing cesarean delivery who received 600 mg IV 30 minutes before surgery, umbilical cord blood concentrations were 46% of maternal serum levels. 20 After multiple oral doses prior to therapeutic abortion, fetal blood concentrations were 25% and amniotic fluid levels were 30% of maternal blood levels. 21 Excreted in human breast milk (Product information Clindamycin, 1970). Considered "usually compatible with breastfeeding."
At maternal doses of 150 mg orally to 600 mg IV, breast milk concentrations range from 0.7 to 3.8 g/mL
(Product information
Clindamycin, 1970).
Pharmacokinetic parameters do not change during pregnancy in women studied during the 1st, 2nd, and 3rd trimesters of gestation. 20, 24 There are no studies to indicate that dosing should be modified during pregnancy. Excreted in human breast milk. 25 Use for a short period (1 week) during breastfeeding is considered probably safe. 9, 16 Breast milk concentrations are 30-40% of that found in maternal blood. Excreted in human breast milk. 29, 30 Considered "usually compatible with breastfeeding."
Poorly absorbed from the GI tract. 29 Only half of nursing newborns had detectable serum levels, which were low and not likely to cause clinical effects. 29 No adverse signs or symptoms in nursing infants as a result of maternal treatment. 9 Increased dosage suggested due to decreased serum half-life in pregnancy and lower maternal serum levels. 20, 31 In 54 women undergoing cesarean delivery, levels were lower than nonpregnant women. 5, 33, 34 Penicillins are transferred to the fetus and amniotic fluid reaching therapeutic levels. 5 Excreted in human breast milk in small amounts (Product information Bicillin, 2001; product information Penicillin V, 1997).
15
Considered "usually compatible with breastfeeding." 9 † In women with serum concentrations of penicillin ranging from 6 to 120 g/dL, corresponding breast milk concentrations were 1.2-3.6 g/dL, and the amount of the maternal dose appearing in breast milk per day was estimated at 0.03%. 15 Shorter dosing interval and/ or increased dose have been suggested during pregnancy to attain similar plasma concentrations as for nonpregnant women. 6, 11 Penicillins are primarily renally excreted via tubular secretion and glomerular filtration. Volume of distribution and renal clearance are increased during the 2nd and 3rd trimesters. 6, 11 Penicillin VK Gram-positive aerobes including most streptococci/ enterococci, grampositive anaerobes, gram negatives Crosses the human placenta readily. 5, 7, 10, 33, 34, 35 Penicillins are transferred to the fetus and amniotic fluid reaching therapeutic levels. 5 Excreted in human breast milk in small amounts (Product information Penicillin V, 1997). 15, 36 Considered "usually compatible with breastfeeding." [37] [38] [39] Umbilical cord concentrations between 12% and 33% of maternal blood levels, with peak levels occurring concurrently after drug administration. [37] [38] [39] Excreted in human breast milk (Product information Rifampin, 1971). CBC, complete blood count; AF, amniotic fluid; MS, maternal serum; GI, gastrointestinal; AUC, area under the curve; GFR, glomerular filtration rate.
* Listed in the product label and the clinical pharmacology monograph as active against most strains; bacterial resistance occurs commonly in some species of otherwise susceptible bacteria due to beta-lactamase production. † Based on assessment by the American Academy of Pediatrics. No increased rate of congenital malformations among 147 women who received prescriptions for amoxicillin during the 1st trimester. 46 No increased rate of congenital anomalies among 284 infants whose mothers were administered amoxicillin or ampicillin during the 1st trimester, or in 1,060 infants whose mothers were treated at any time during pregnancy. 47 No significantly increased rate of major or minor anomalies in the children of 14 women treated with amoxicillin and probenecid during the first 14 weeks of gestation or among 57 women treated after the 14th week in a controlled clinical trial on the treatment of gonorrhea during pregnancy. 48 No adverse effects in offspring exposed to amoxicillin during the 2nd and 3rd trimesters in 3 controlled clinical trials of antibiotic treatment for premature preterm rupture of membranes. [49] [50] [51] An association of necrotizing enterocolitis in newborns and maternal amoxicillin and clavulanic acid treatment during the 3rd trimester was observed in a randomized controlled trial including 4,826 pregnant patients. 52, 53 No increased congenital malformations in mice treated with 3-7 times the maximum human therapeutic dose of amoxicillin. 54 No adverse reproductive effects in rats given amoxicillinclavulanic acid at doses of 400 and 1,200 mg/day prior to fertilization and during the first 7 days of gestation (Product information Amoxil, 2001). 55 No adverse fetal effects in pigs given amoxicillin with clavulanic acid at doses of 600 mg/kg on days 12-42.
56
Increased frequency of embryonic death in mice treated with amoxicillin at 6-7 times the maximum therapeutic human dose. 54 Increased risk of teratogenicity is "unlikely," based on "fair" data.
B
Chloramphenicol OR for major congenital anomalies ϭ 1.7 (95% CI 1.2-2.6) for oral administration at any time during pregnancy in a casecontrol study of 22,865 malformed infants (risk marginally increased). 57 RR for congenital malformations ϭ
(95% CI 0.52-2.31) in
348 offspring born to women who took chloramphenicol at any time during pregnancy (no statistically increased risk). 58 Potential for both dose-related and idiosyncratic bone marrow toxicity. Caution should be used near term, during labor, and while breastfeeding due to the possibility of inducing "gray-baby" syndrome. 59 No increased congenital anomalies in monkeys. 60 No teratogenicity in mice or rabbits at 10-40 times the recommended human dose. 61 No teratogenicity in rats at 2-4 times the usual human dose, 62 but various fetal anomalies at 10-40 times the human dose.
61,63
Increased fetal death and decreased fetal weight in mice, rats, and rabbits. [61] [62] [63] Increased risk of teratogenicity is "unlikely," based on "fair" data. "Therapeutic doses of chloramphenicol are unlikely to pose a substantial teratogenic risk." [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] . Rates of spontaneous abortion/fetal death, post-natal disorders, prematurity and intra-uterine growth retardation did not exceed background rates. 64 In a prospective registry of 116 pregnancies exposed to ciprofloxacin, 91 resulted in live births and 69% of these were exposed during the 1st trimester. Six liveborns were malformed (congenital malformation rate ϭ 6.6%). There was no pattern of minor or major malformations. 64 OR for major congenital anomalies ϭ 0.85 (95% CI 0.21-3.49) in a controlled, prospective, observational study of 200 human pregnancies exposed to fluoroquinolones during the 1st trimester (2.2% rate versus 2.6% in controls) [53% ciprofloxacin exposures, with 68% during the 1st trimester] (no increased risk). 65 No clinically significant musculoskeletal or developmental dysfunctions in offspring. 65 No congenital malformations and no increase in musculoskeletal problems in offspring of 28 pregnant women exposed to ciprofloxacin during the 1st trimester. 65 Permanent quinolone-induced cartilage or bone damage has not been documented in humans. 66, 67 Seven women exposed to ciprofloxacin during 2nd or 3rd trimester delivered healthy, normal babies. Motor, adaptive, social, and language milestones were consistent with age, and there was no evidence of cartilage damage on regular clinical assessments up to 5 years of age. 68 No detectable adverse effects on embryonic or fetal development in monkeys. 69 No evidence of teratogenicity in the offspring of mice, rats, and rabbits. 70 Increased risk of teratogenicity is "unlikely," based on "fair" data. "Therapeutic doses of ciprofloxacin during pregnancy are unlikely to pose a substantial teratogenic risk, but the data are insufficient to state that there is no [increased] risk".
C Clindamycin
Major congenital anomalies in 31 of 647 infants (4.8%) whose mothers were given prescriptions for clindamycin during the 1st trimester of pregnancy; expected rate 4.3%. 71 No increased rate of congenital malformations in 104 women treated with clindamycin during the 2nd or 3rd trimester of pregnancy for the prevention of preterm delivery. 72 No increased rate of congenital anomalies in 65 infants born to women who received clindamycin and quinine during the 2nd or 3rd trimester of pregnancy for the treatment of malaria. 73 No increased congenital malformations in mice and rats given 1-12 times the therapeutic human dose. 77, 78 Increased risk of teratogenicity is "undetermined" based on "limited" No congenital malformations among 16 children of women treated with clindamycin during the 1st trimester of pregnancy for attempted prevention of recurrent miscarriage. 74 Can be a causative factor in the development of pseudomembranous colitis due to overgrowth of Clostridium difficile. Occurs infrequently and no more common among pregnant women using clindamycin than nonpregnant. 75 Has occurred with use of nearly all antibacterial agents, including clindamycin (Product information Clindamycin, 1970 ). An infant developed bloody stools after exposure to clindamycin and gentamicin in breast milk; no blood and breast milk samples were obtained and a causative relationship was not established. for women receiving doxycycline at any time during pregnancy in a case-control study of 18,515 infants with congenital abnormalities (risk marginally increased). 79 OR of 1.6 was not significantly increased (95% CI 0.8-3.6) for a separately analyzed subgroup exposed during organogenesis (2-3 months of pregnancy). 79 No association of congenital malformations with doxycycline exposure for any of 6 anomalies (cardiovascular defects, oral clefts, spina bifida, polydactyly, limb reduction defects, and hypospadias) among 1,795 doxycycline-exposed pregnancies in 229,101 completed pregnancies in a surveillance study of Medicaid recipients. 71 All mothers reported that exposed infants were normal at 1 year of age in a prospective study of 81 pregnancies treated with doxycycline for 10 days during the early 1st trimester. 80 Tetracycline class antibiotics may induce hepatic necrosis in some pregnant women. [81] [82] [83] Some tetracyclines can cause cosmetic staining of primary dentition for exposures during the 2nd or 3rd trimester, 84, 85 and there is some concern about possible enamel hypoplasia and reversible depression of fetal bone growth. 86 No staining from doxycycline has been documented in humans.
No increase in congenital anomalies in mice treated with 2-6 times the maximum human dose. 87 Increased skeletal anomalies and decreased fetal weight in mice at 17 times the maximum human dose. 87 No teratogenicity in rabbits given 2-17 times the maximum human dose, but decreased fetal weight and increased fetal death at higher doses. 87, 88 No teratogenicity in rats or monkeys at more than 100 times the human dose. A randomized trial of 3 parenteral antibiotic regimens showed no congenital abnormalities among 57 infants whose mothers were treated with gentamicin during the 1st or 2nd trimesters. 92 The frequency of newborn hearing screening failures was not different between 46 infants whose mothers were treated with gentamicin during pregnancy and 92 unexposed control infants. 93 Renal cystic dysplasia was reported in a child whose mother was given gentamicin during the 7th week of pregnancy. 94 There is no proof of a causal relationship between the gentamicin treatment and the nephrotoxicity, but it cannot be excluded. 94 No ototoxicity or nephrotoxicity has been documented in human fetuses. 44 Mice given 1-12 times the maximum human dose had a slight statistically nonsignificant increase in the rate of congenital anomalies at lower doses, but not higher ones. 95 Fetal deaths were increased. 95 In mice treated with 11-18 times the maximum human dose, dose-dependent ultrastructural vestibular system damage was demonstrated in offspring. 96 In rats treated systemically with daily doses up to 500 times the maximum human ophthalmic dose, gentamicin depressed median glomerular counts and kidney and body weights in newborns (Product information Gentamicin,
1966).
Rats given 9-25 times the maximum human dose had nephrotoxicity in offspring of type typically expected from aminoglycoside exposure. 97 Increased risk of teratogenicity is "undetermined" based on "limited" data. No teratogenicity in rats at oral doses up to 810 mg/kg per day (9.4 times the maximum human dose based on BSA) or IV doses up to 160 mg/kg per day (1.9 times the maximum human dose) (Product information Levaquin, 1996) . There are no well-controlled studies of the safety and efficacy of levofloxacin in pregnant or lactating women. Comprehensive reviews of published data concerning norfloxacin and ciprofloxacin (2 related fluoroquinolone antibiotics) conclude that an increased risk of teratogenicity is "unlikely" based on "fair" data.
C (continued)
1130 Nahum et al Antibiotic Use in Pregnancy OBSTETRICS & GYNECOLOGY for women who used penicillin G during pregnancy in a case-control study (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) of 22,865 malformed infants (marginally increased risk suggested attributable to recall bias by the authors).
99
RR for congenital malformations ϭ 0.92 (95% CI 0.78-1.10) among 7,171 infants whose mothers were treated with a penicillin derivative at any time during pregnancy (no increased risk). 58 The frequency of 1st-trimester penicillin use was no greater than expected in a prospective study of 194 infants with major malformations born in Sweden (1963 Sweden ( -1965 . 100 OR for neural tube defects ϭ 0.90 (95% CI 0.37-2.17). Rate of 1st-trimester penicillin use was no greater than expected in a case-control study of 538 infants with neural tube defects and 539 controls in California from 1989 to 1991 (no increased risk). 101 No adverse effects noted in offspring despite widespread use of penicillins during pregnancy. 10, 44, 58, 99, 102 No teratogenicity in mice administered up to 500 units/g on gestation day 14.
103
No teratogenicity or increased abortions in rabbits maintained on 100 mg/kg per day during pregnancy. 104 No teratogenicity or impaired fertility in mice, rats and rabbits (Product information Bicillin, 2001). Increased risk of teratogenicity is "none" based on "good" data. congenital malformations among 410 offspring in 442 gravidas treated with rifampin-usually in combination with other drugs-was 3.3% and no higher than expected for human populations. 44, 107 Exposure was during the first 4 months in 109 cases. The spontaneous abortion rate ϭ
1.7%
was below expected for a general obstetrical population. 108 In 226 women exposed during 229 conceptions, 9 offspring had congenital malformations among 207 births (4.3%) 37, 109 ; this was no greater than the historical rate for women afflicted with tuberculosis.
37,109
The spontaneous abortion rate ϭ
2.4%
and was below expected for general obstetric populations. 108 No congenital anomalies in the offspring of 13 women treated with rifampin for leprosy, 110 or 18 women treated for brucellosis.
111
Treatment occurred during all trimesters.
No increased rate of congenital anomalies in rats or mice treated with 2.5-10 times the usual human dose. No congenital abnormality in the newborn of a woman who received 28 days of 1 g q12 hours IV beginning at 13 weeks of pregnancy. 114 The highest peak level measured was 20 g/mL.
A fetal bradycardia occurred in a pregnant woman who developed hypotension when vancomycin was infused rapidly IV during labor, but there were no adverse effects on the child. 115 Vancomycin is potentially ototoxic and nephrotoxic. However, 10 pregnant women who received 1 g q12 hours IV for at least 1 week had no maternal ototoxicity or nephrotoxicity. 42 In a pregnant woman who was treated IV twice daily for 13 days, there was no maternal ototoxicity or nephrotoxicity. 43 The risk of these toxic effects in the fetus is considered low. 42, 44 No cokinetic data were available in lactating women for any of the antibiotics (Table 2 ).
CONCLUSION
The safety of drug use in pregnancy is often an enigma. Many drugs have a long usage history in pregnancy without any controlled clinical trials ever having been conducted to ascertain their safety or efficacy during human pregnancy. Although there is little reason to believe that medications that have been demonstrated to be effective for particular conditions in nonpregnant subjects will not also prove effective when delivered in proper doses to pregnant women, the changes in basic physiology that occur in the maternal volume of distribution, renal clearance, and hepatic metabolism-as well as the potential for pharmacokinetic effects related to the distribution and metabolism of the drug in the fetal compartmentmake the issue of proper pregnancy-specific dosing difficult to predict in the absence of empirical data. To further complicate this issue, these physiologic changes of pregnancy vary greatly from the first to the third trimester. Often, because of inadequate data regarding the prevalence of use, timing, and duration of exposure of sufficient numbers of pregnant women to drugs, there is insufficient information to formulate conclusive judgments about their safety and efficacy that are different from that for nonpregnant patients. Concerns regarding potential teratogenicity and fetal or neonatal toxicity are often incompletely addressed by the limited amount of pregnancy and lactation exposure data and adverse event reports that are available. Because of this, conflicts can arise between the theoretical fear of adverse fetal or neonatal consequences and the general bias among most healthcare professionals that the successful treatment of medical conditions in the mother is in the offspring's best interest. This is especially true in the case of potentially life-threatening illnesses, as is the case with many agents of bioterrorism. These issues are particularly relevant to emergency response professionals, as well as to primary health care providers who manage the pregnancies of the nearly four million women who deliver newborns each year in the United States. 2 The difficulty with the assessment of drug effects in pregnant women is typically related to a lack of well-controlled clinical data concerning the pharmacokinetics and pharmacodynamics of their use in pregnancy. Assessments that pertain to rare adverse events typically rely on the analysis of retrospective case-control data and, less often, on prospective cohort series. By using these data, it is often possible to place bounds on the risk of teratogenicity and fetal or neonatal toxicities that may result from medication use during pregnancy and lactation and to make reasonable judgments as to the safety of different medications, in addition to estimates concerning their proper dosing. A summary of these findings-based on the available data for 11 widely used broadspectrum antibiotics-is presented in Tables 2 and 3 . When indicated and properly administered, all of these agents seem to have sufficient evidence to allow for their use during pregnancy and lactation. Antibiotic use in pregnant and lactating women has become an increasing concern due to the threat of bioterrorism. Because the timing and type of a bioterrorist attack is necessarily unpredictable, health care providers must be aware of the different types of diseases and potential treatment options that may be needed in these circumstances ( Table 5 ). The situation is further complicated because the data that pertain to medications for combating these agents are derived primarily from in vitro susceptibility studies in limited numbers of clinical isolates that were obtained from nonpregnant patients. Many of the treatment regimens that are currently recommended by the Centers for Disease Control and Prevention for these bioterrorist agents and their associated diseases are not currently FDA-approved indications because of the lack of adequate and well-controlled clinical trials to support their efficacy and safety under these circumstances. Sometimes they may have been approved based on surrogate markers or endpoints (ie, 21 CFR 314 Subpart H) or only animal data based on the animal efficacy rule (ie, 21 CFR 314 Subpart I). 124, 125 Thus, the issues of teratogenicity and fetal toxicity, as well as additional concerns surrounding the potential need for differential dosing of these drugs during pregnancy under these circumstances, have an intrinsically limited amount of data from which to draw.
The focus of this article has been to evaluate the existing data within the public domain with regard to 11 broad-spectrum antibiotics that can be of potential use in pregnant and lactating women. All are currently available for the treatment of routine and life-threatening bacterial infections, in addition to exposures associated with some known potential agents of bioterrorism. In the unlikely case of a bioterrorist attack, all health care providers must be able to provide their patients with appropriate treatment or prophylaxis after critical exposures. Pregnant and lactating women are a particularly vulnerable population and health care professionals should be familiar with the antibiotics that can be used under such adverse circumstances to feel confident in treating such pathogenic exposures.
